Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReFacto AF safety and efficacy study in previously untreated young children with severe hemophilia A
2008-008436-93Phase 4Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human coagulation factor VIII in hemophilia A, sponsored by Pfizer. Primary endpoint: Proportion of patients who develop clinically significant FVIII inhibitors. Started May 2009; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2008-008436-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008436-93.